Swiss biotech Windward Bio files for Nasdaq IPO to raise funds for China-derived assets and R&D

Windward Bio, a Basel-based European biotech founded two years ago, announced it has filed its registration statements to list on Nasdaq.

The company plans to use the proceeds to support two clinical-stage programs that originated in China, as well as to expand its internal research and development capabilities.

The filing marks the latest attempt by a young biotech with China-derived assets to access U.S. public markets, highlighting growing investor interest in cross-border drug development.